Ticas

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ticas

Ticas: Defining its Active Component and Class

Property Description
Active ingredient Fluticasone Propionate
Form Inhaler, Nasal Spray, Cream, Ointment
Pharmacological class Synthetic Glucocorticoid (Corticosteroid)
General purpose Localized anti-inflammatory and anti-allergic action
Origin Synthetic

Ticas is the trade name for a medicinal preparation whose active component is Fluticasone Propionate, a highly potent member of the synthetic glucocorticoid class. Fluticasone Propionate is a type of corticosteroid chemically engineered to exert a powerful anti-inflammatory effect. This substance is utilized to reduce swelling and irritation in the body.


As a synthetic compound, Fluticasone Propionate is designed to mimic the action of natural hormones but with increased potency and a focus on localized activity. This distinction is clinically recognized for providing high efficacy specifically at the application site. The core identity of Ticas, therefore, is rooted in its highly effective, targeted ability to control the body’s unwarranted or excessive immune responses.

Available Forms and Targeted Delivery

Ticas is manufactured as a single-ingredient product in several dosage forms to ensure the active component is delivered precisely to the required local site. The primary forms include an inhaler (aerosol or dry powder) for Inhalation into the lungs, a nasal spray for Intranasal administration, and creams or ointments for Topical application. These inhaled and intranasal applications are characterized by low systemic bioavailability.


The form dictates the specific composition, as each must carry the active component, Fluticasone Propionate, in an optimal base—such as an aqueous vehicle for nasal use or a propellant for inhalation. This versatility allows the potent anti-inflammatory action to be directly concentrated on surfaces like the airways or skin, which is a key feature of the drug's design.

Primary Purpose: Anti-Inflammatory and Allergy Control

The general purpose of Ticas is to provide potent, localized relief by systematically suppressing the multiple chemical reactions responsible for inflammation and allergic hyperactivity. It achieves this by inhibiting the release of key inflammatory mediators, including cytokines, prostaglandins, and histamine, directly at the source of irritation. The resulting practical benefit for the patient is the general alleviation of allergic symptoms and the reduction of tissue swelling, which is a typical use scenario when managing chronic local inflammation.

Regulatory References

  1. MedlinePlus

What side effects are possible with Ticas?

Possible Side Effects and Safety Information

The safety profile of Ticas (Fluticasone Propionate) is structured around the potential for localized adverse reactions at the site of administration, alongside a risk of systemic corticosteroid effects documented in official regulatory labels. The frequency of these reactions is classified based on regulatory standards (e.g., EMA/FDA).


Regulatory Classification of Adverse Reactions

Common reactions (occurring in 1 out of 10 to 1 out of 100 people) primarily involve the administration site. For example, the nasal form is commonly associated with epistaxis (nosebleed) and headache. Inhaled forms may commonly lead to oral candidiasis (thrush) and dysphonia (hoarseness), which are addressed under the Infections and Infestations and Respiratory Disorders system-organ classes, respectively.

Less frequently, rare to very rare serious adverse reactions have been documented in official labeling. These include systemic effects such as adrenal suppression and manifestations of Hypercorticism, classified under Endocrine Disorders. Ocular concerns, including Glaucoma and Cataracts, are also noted safety risks associated with prolonged use and classified under Eye Disorders.


Exposure Patterns and Safety Constraints

The regulatory safety notes emphasize that the risk of systemic effects, such as HPA axis suppression and the development of ocular issues, may be heightened with long-term exposure or when high dosages are used. Furthermore, the label includes safety restrictions regarding co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole), as these can significantly increase the systemic exposure to Fluticasone Propionate.

Specific population-based safety statements are also present: official documents advise monitoring growth velocity in pediatric patients due to the potential for growth reduction, and caution is warranted in individuals with moderate to severe hepatic impairment due to the drug's metabolism.

Overdose and Emergency Response

Overdose and When to Seek Help

Ticas (Ticagrelor) is an antiplatelet medication, and the primary risk associated with an overdose is an enhanced antiplateplatelet effect, leading to an increased and potentially life-threatening bleeding risk.

Symptoms of Overdose

Symptoms of a Ticas overdose are generally an exaggeration of the drug's therapeutic effects and include:

  • Bleeding: Increased bruising, nosebleeds, and prolonged bleeding time. Severe overdose can lead to major hemorrhage, such as gastrointestinal bleeding or intracranial hemorrhage (bleeding in the brain).
  • Gastrointestinal Effects: Nausea, vomiting, and diarrhea.
  • Cardiac Effects: May include an irregular heartbeat (arrhythmia) and slow heart rate (bradycardia).

When to Seek Immediate Medical Help

An overdose of Ticas is a medical emergency. You must seek emergency medical attention immediately if you or someone else has taken more than the prescribed dose or if any of the following severe symptoms occur:

  • Bleeding that is severe, prolonged, or uncontrollable.
  • Vomiting blood or material that looks like coffee grounds.
  • Stools that are black, tarry, or bloody.
  • Pink, red, or brown urine.
  • Coughing up blood or blood clots.
  • Signs of a potential stroke, such as sudden confusion, slurred speech, or weakness on one side of the body.
  • Fainting, seizure, or loss of consciousness.

Treatment for Ticas overdose is mainly supportive and focuses on managing bleeding complications. If an overdose is suspected, contact a poison control center or emergency services immediately.

Therapeutic Uses of Ticas

Ticas is commonly used in areas where additional symptomatic support is needed across primary areas of the body, helping patients manage symptoms that interfere with daily functioning and overall comfort. The medication is relevant when supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms.

The medication is relevant for managing symptoms that interfere with daily comfort across three key areas: it is used for managing persistent asthma, allergic and non-allergic rhinitis, nasal polyps, and conditions like eczema (atopic dermatitis) and corticosteroid-responsive dermatoses.

This action helps address symptom clusters that may become intense or disruptive, such as persistent wheezing, excessive nasal congestion, and severe pruritus (itching).

“This application provides supportive relief that helps patients cope more steadily with difficult episodes, assisting with maintaining functional stability.”

Quick Fact: Relief for Inflammatory Symptoms

Ticas is applied in clinical settings that involve acute or unstable symptom patterns, helping to ease the overall symptom burden relevant in contexts involving heightened systemic burden in the airways, nasal passages, and skin. It contributes to improved comfort during symptomatic periods.

Regulatory References

  1. National Library of Medicine's DailyMed overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ticas — official regulatory information

Ticas (Ticagrelor) is an antiplatelet medication, and official regulatory documents define strict limitations on its use primarily due to the associated risk of bleeding.


Eligibility scope

Population Status Classification and Rule (Regulatory Basis)
Contraindicated Patients with a history of intracranial hemorrhage or with active pathological bleeding (e.g., peptic ulcer).
Contraindicated Patients with hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product.
Contraindicated Patients with severe hepatic impairment (due to likely increased drug exposure and bleeding risk).
Not Recommended Patients undergoing urgent coronary artery bypass graft (CABG) surgery (treatment initiation is generally prohibited).
Restricted Use Pregnancy and Lactation (Safety has not been established; use is generally not recommended, and a decision to discontinue the drug or nursing must be made).
Conditional Use Patients with moderate hepatic impairment (limited experience exists; caution is advised).
Use Not Established Pediatric patients (Safety and effectiveness in those under 18 years of age have not been established).

Connection to the overall eligibility profile

The regulatory profile clearly establishes absolute exclusions, or contraindications, for populations where the risk of hemorrhage is critically high or where metabolic clearance is severely impaired. Further restrictions are applied to populations lacking sufficient data, such as children, or where the known risks outweigh the benefits, such as during pregnancy and breastfeeding. These formal classifications strictly govern who may be prescribed the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Ticas (Fluticasone Propionate) focuses on interactions that can alter the body’s exposure to the medication, primarily through its metabolic pathway. Ticas is extensively cleared from the body through the action of the Cytochrome P450 3A4 (CYP3A4) enzyme, which forms the basis for its documented interaction profile.


Documented Pharmacokinetic Interactions

Ticas is not recommended for co-administration with medicinal products that are strong inhibitors of the CYP3A4 enzyme. This combination decreases the clearance of Fluticasone Propionate, leading to a significant increase in the systemic drug levels (exposure).

The regulatory labels specifically cite the following as examples of strong CYP3A4 inhibitors known to interact:

  • Ritonavir (an antiretroviral agent)
  • Ketoconazole (an antifungal agent)

Population-Specific Caution

Because Ticas relies heavily on hepatic (liver) metabolism for its elimination, patients with severe hepatic impairment may experience increased systemic exposure to the drug. This note addresses a heightened interaction risk in this specific population due to their reduced ability to clear the medication.


Contraindicated Combinations

No universally prohibited drug-drug combinations (formal contraindications) are listed for Ticas based solely on interaction risk in the primary regulatory labels examined.

Mechanism of Action

The mechanism of Fluticasone Propionate is defined by three interconnected mechanistic domains that systematically control inflammation at the molecular level, concentrating its effects locally.

Regulating Inflammation at the Genetic Level

The drug acts as a high-affinity agonist at the intracellular Glucocorticoid Receptor (GR), initiating a change in gene expression. The activated receptor complex moves into the nucleus to physically repress pro-inflammatory transcription factors like NF-kappaB, thereby suppressing the genes responsible for generating chemical inflammatory signals (e.g., cytokines and prostaglandins). This transcriptional blockade results in a systematic suppression of the molecular drivers involved in heightened physiological responses.

Modulation of Immune Cells and Chemical Messengers

A secondary consequence of this gene modulation is the modulation of the cells and mediators that execute the inflammatory response. The mechanism promotes apoptosis (programmed cell death) in key inflammatory cells, such as eosinophils, and inhibits the release of a broad array of chemical messengers, including leukotrienes and histamine. This collective action on the cellular and signaling level reduces the concentration of inflammatory mediators and cells within the targeted tissue.

Localized Control of Fluid Leakage and Blood Flow

Finally, the drug mechanism exerts influence on the vascular system by causing local vasoconstriction and reducing the permeability (leakage) of capillaries at the site of administration. This physical containment effect limits the influx of fluid and additional immune cells from the bloodstream into the tissue, resulting in a decrease in tissue fluid exudate and local blood flow.

Dosage and Administration Information

How to Use Ticas (Administration Guidelines)

These instructions outline the required use of the medicine as specified by standardized guidelines and are strictly descriptive of the prescribed method. The product is an extended-release capsule intended for oral administration.

Dosing Schedule and Regimen

Administration Component Administration Instruction
Route of Administration Oral
Frequency Pattern Once daily
Initial Dose 120 mg to 240 mg
Maximum Daily Dose 540 mg

Procedural Administration Steps

The medicine is designed for a once-daily schedule. It may be taken with or without food.

  1. Take the prescribed dose one time each day.
  2. The capsule must be swallowed whole.
  3. Do not chew, crush, or break the extended-release capsule. Altering the capsule structure prevents the medicine from releasing slowly throughout the day as designed.

Usage Context

Adherence to the proper swallowing procedure is a critical requirement for effective use, as the extended-release properties depend on the capsule remaining intact after ingestion. The initial dose is set within the 120 mg to 240 mg range, and a healthcare professional will titrate the dosage as needed, up to the maximum of 540 mg per day. These rules structure the standardized, correct way to take the medicine and ensure the drug’s intended release profile is maintained.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ticas (Fluticasone Propionate)

Evidence for Airway Maintenance (Persistent Asthma)

The research base for Ticas includes Randomized Controlled Trials (RCTs) and systematic reviews, which explored conditions characterized by fluctuating or episodic manifestations. These studies monitored outcomes related to systemic or functional imbalance, such as specific lung function measurements including the Forced Expiratory Volume in 1 second ( FEV1) and Peak Expiratory Flow (PEF). Research also monitored the number of asthma exacerbations and measured the frequency of rescue medication usage. The findings describe patterns observed in the studies where groups receiving the substance recorded a change in the objective functional lung parameters compared to groups receiving non-active treatments.

Evidence for Nasal and Sinus Conditions (Rhinitis and Polyps)

The intranasal form of Ticas was evaluated in numerous RCTs and comparative trials for conditions like seasonal or perennial rhinitis. The outcomes studied were related to physical discomfort, primarily focusing on change in the Total Nasal Symptom Score (TNSS). For nasal polyps, studies recorded measurements of polyp size and described patterns associated with the substance's use. Research describes how the data show patterns related to some variability when evaluating the results against other active comparator treatments.

What is Still Uncertain About Ticas’ Research Record

The evidence base, while extensive, highlights areas where certainty remains low. Research suggests that a clear dose-response relationship for all outcomes in patients with milder forms of asthma is not consistently described. Furthermore, research describes how the data for certain groups remain insufficient, specifically concerning long-term effects in very young children and the consistency of outcomes for observation beyond a few years. Findings describe group patterns, not personal outcomes, and research does not offer predictions for individual patient outcomes.

Frequently Asked Questions (FAQ)

Common questions about Ticas (FAQ)

Q: Does Ticas cause weight gain or loss?

A: Weight changes are not frequently reported with the recommended use of Ticas formulations. However, official regulatory summaries note that weight gain has been reported as a rare or very rare side effect, particularly when systemic absorption occurs due to high doses or long-term use. This may be related to systemic effects of corticosteroids, such as signs of Cushing's syndrome.

Q: Can Ticas affect my blood pressure?

A: Since Ticas is primarily intended for localized action, high blood pressure (hypertension) is not commonly reported as a side effect. Regulatory safety data, however, has rarely documented this as a potential serious systemic effect associated with the use of high doses or prolonged exposure to the corticosteroid component.

Q: Will Ticas show up on a drug test?

A: Ticas contains Fluticasone Propionate, a synthetic glucocorticoid (corticosteroid). Regulatory classification indicates that it is not generally among the substances screened for in standard drug tests for substances of abuse.

Q: Does Ticas affect sleep?

A: Sleep disturbance is not listed as a common side effect of Ticas. However, in regulatory safety information, very rare side effects involving the nervous system, such as agitation, restlessness, or insomnia (difficulty sleeping), have been noted.

Q: Can Ticas cause stomach problems?

A: Yes, some gastrointestinal issues are mentioned in the official regulatory documentation. Depending on the formulation, side effects such as nausea, vomiting, or abdominal discomfort are reported as less common or common adverse reactions.

Q: How long does the effect of Ticas last in the body?

A: The amount of Ticas that is systemically absorbed has a terminal half-life of around 7 to 8 hours. The active component is largely eliminated from the body within a few days, as per pharmacokinetics data.

Q: Are there any long-term effects of taking Ticas?

A: Regulatory documents state that using Ticas long-term, especially at higher-than-recommended doses, carries risks of systemic effects. These concerns include adrenal suppression, reduced bone density, and eye disorders like cataracts and glaucoma.

Q: Should I avoid certain foods or drinks while on Ticas?

A: The official interaction profile highlights the importance of discussing the use of strong CYP3A4 enzyme inhibitors with a healthcare professional. Some regulatory documents also specifically mention that consuming grapefruit juice should be discussed with a provider, as it can increase the body's exposure to the medication.

Q: Has dizziness been reported after starting Ticas?

A: Dizziness is not listed as a common adverse reaction in the official product information. However, dizziness has been reported in regulatory safety data as a very rare side effect associated with the use of Ticas.

Q: What is the main benefit people seek when they take Ticas?

A: Official information indicates that Ticas is used for the maintenance treatment of chronic conditions, with the goal of reducing inflammation and preventing symptoms. This action can lead to an improvement in functional outcomes, such as better lung capacity or fewer allergy symptoms.

Q: Are there specific symptoms that get better first when starting Ticas?

A: Regulatory documents indicate that for certain formulations, some initial effects may be observed as early as 8 hours after the first dose. However, the time frame to achieve maximum or full therapeutic benefits varies and may take several days or longer.

Q: Do I need regular blood tests while taking Ticas?

A: Official regulatory information notes that monitoring is sometimes required for patients who are transitioning from oral steroids or using higher doses. This monitoring is typically done to check for potential signs of adrenal suppression.

Q: Can Ticas interact with common pain relievers?

A: While the official interaction profile highlights CYP3A4 inhibitors, common pain relievers like ibuprofen or acetaminophen are not typically listed as being contraindicated. However, discussing all medications, including over-the-counter products, with a healthcare professional is always advised.

Q: Is Ticas used for short-term or long-term issues?

A: Ticas is indicated for the maintenance treatment of chronic conditions. It is generally intended to be used as a long-term, prophylactic (preventive) therapy, rather than for providing relief for acute or sudden symptoms.

Q: Can Ticas cause any vision changes?

A: Yes, official regulatory labels state that prolonged use of Ticas is associated with a risk of eye disorders. Serious effects noted include glaucoma and cataracts, and blurred vision has also been reported as a potential side effect.

Q: Are there any warnings about Ticas and driving or operating machinery?

A: Regulatory information states that Ticas has only a minor influence on the ability to drive or use machines. If effects like fatigue or dizziness are experienced, caution should be used when engaging in activities that require complete mental alertness.

Q: How is Ticas eliminated from the body?

A: The small amount of Ticas that is absorbed into the bloodstream is processed by the liver. The drug is then primarily eliminated from the body through excretion in the feces, with only a small amount being passed through the urine, according to pharmacokinetics data.

Q: What should I do if I think I'm having a serious side effect from Ticas?

A: Official regulatory documents advise that immediate medical help should be sought for signs of a severe allergic reaction, such as swelling of the face, lips, or tongue. Contacting a healthcare professional is also advised right away if other serious side effects, such as vision changes or signs of a new infection, are experienced.

Q: Does Ticas cause dry mouth?

A: Dry mouth is not listed among the most common adverse reactions to Ticas. However, it has been reported as an uncommon or rare side effect in regulatory safety data for some formulations of the drug.

Q: Is Ticas considered a 'highly potent' medicine?

A: The active ingredient in Ticas, Fluticasone Propionate, is officially defined as a highly potent synthetic glucocorticoid. This classification highlights its powerful anti-inflammatory action at the specific site where the medication is delivered.

Q: Has Ticas been studied in pregnant women?

A: Regulatory labels state that there are no adequate and well-controlled studies specifically on Ticas use in pregnant women. Official guidance states that the decision to use the medicine during pregnancy must be made by a healthcare provider after a careful assessment of the potential benefits versus the potential risks.

How should Ticas be stored and disposed of?

Official Storage and Disposal Requirements for Ticas

Regulatory documents specify strict conditions for storing and disposing of Ticas to maintain its effectiveness and safety.

Storage Conditions

Ticas must be stored at Controlled Room Temperature, typically maintained between 15 C to 30 C (59 F to 86 F). The product must be protected from both light and moisture. Do not freeze the medicine, as this can affect its stability. The original packaging must be retained until use. For products that require mixing or are sensitive after opening, specific in-use stability periods are defined (e.g., discard after a set number of days/weeks).

Disposal and Handling

It is mandatory to keep Ticas out of the sight and reach of children at all times. Unused or expired medication should not be discarded in household trash or poured down a drain. Instead, follow official pharmaceutical waste guidelines, such as utilizing a drug take-back program or following specific federal instructions for safe household disposal, to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ticas found in:

A-Z Index: